Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 19/20 | 0.69 |
| ▸ | NPY1R | P25929 | 11/20 | 0.69 |
| ▸ | NPY5R | Q15761 | 10/20 | 0.69 |
| ▸ | NPY2R | P49146 | 7/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14702343 | 0.93 | NPY4R (0.61) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL11129760 | 0.90 | NPY4R (0.60) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL16728103 | 0.90 | NPY4R (0.68) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL20902772 | 0.90 | NPY4R (0.68) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL12792696 | 0.89 | NPY4R (0.73) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL13563464 | 0.89 | NPY4R (0.73) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL13563459 | 0.88 | NPY4R (0.77) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL15681487 | 0.88 | NPY4R (0.77) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL12417393 | 0.88 | NPY4R (0.68) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL12417431 | 0.88 | NPY4R (0.68) | NPY4RNPY1RNPY5RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12023378-B2 | Covalently linked antigen-antibody conjugates | HOFFMANN-LA ROCHE INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-11273223-B2 | Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles | HOFFMANN-LA ROCHE INC. (US) | 2022-03-15 | — | — | US | disclosed |
| EP-3068421-B1 | SELECTIVE PYY COMPOUNDS AND USES THEREOF | NOVO NORDISK AS (DK) | 2019-04-17 | — | — | EP | disclosed |
| US-10246497-B2 | Selective PYY compounds and uses thereof | NOVO NORDISK A/S (DK) | 2019-04-02 | — | — | US | disclosed |
| WO-2015071355-A1 | SELECTIVE PYY COMPOUNDS AND USES THEREOF | NOVO NORDISK A/S (DK) | 2015-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10246497-B2 | Selective PYY compounds and uses thereof | NPY1R, NPY5R, NPY2R | NPY4R 4/4885NPY1R 1/4885NPY5R 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.